Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin
among Asians with non-valvular atrial fibrillation (NVAF) remains unclear in the real-world …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …

Background This study was designed to compare efficacy and safety among novel oral
anticoagulants (NOACs), which have not been directly compared in randomized control …

Background—Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral
factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in …